Meropenem Steriscience

Meropenem, the active ingredient in Meropenem Steriscience, is a carbapenem antibiotic presented as a sterile powder for reconstitution for intravenous use. It treats severe bacterial infections such as intra‑abdominal, urinary tract, respiratory and bloodstream infections in hospitalized adult patients. It is administered under medical supervision in acute care settings.

GNH USA supplies Meropenem Steriscience as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide, providing reliable, quality‑assured products to healthcare institutions across multiple continents. The company adheres to stringent quality standards and regulatory requirements to ensure product integrity.

Meropenem is a broad‑spectrum carbapenem antibiotic indicated for serious bacterial infections affecting various organ systems.

- Complicated intra‑abdominal infections: achieves bacterial eradication in the peritoneal cavity and reduces postoperative infection risk. - Complicated urinary tract infections: provides effective coverage against resistant uropathogens and promotes rapid symptom resolution. - Hospital‑acquired pneumonia: targets multidrug‑resistant respiratory pathogens, improving clinical cure rates. - Septicemia: delivers systemic bactericidal activity to control bloodstream infection and prevent organ failure.

Like all antibiotics, meropenem may cause adverse reactions ranging from mild to severe.

Common Side Effects: - Nausea: mild gastrointestinal upset. - Diarrhea: may be watery and self‑limiting. - Headache: transient cranial discomfort. - Elevated liver enzymes: mild hepatic enzyme rise.

Serious or Rare Side Effects: - Anaphylaxis: severe allergic reaction requiring immediate medical attention. - Seizures: particularly in patients with renal impairment or CNS disorders. - Clostridioides difficile infection: colitis due to disruption of normal gut flora. - Neutropenia: significant reduction in white blood cell count.

Clinicians should consider several safety measures when prescribing meropenem.

- Renal function: adjust dose in patients with impaired kidney function. - Hypersensitivity: avoid in individuals with known allergy to β‑lactam antibiotics. - Concomitant CNS disease: monitor for seizures in patients with epilepsy or brain injury. - Pregnancy and lactation: use only if benefits outweigh potential risks, as safety data are limited. - Drug‑induced liver injury: monitor liver function tests during prolonged therapy. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Meropenem may interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - Valproic acid: concurrent use can reduce valproate levels, risking seizure breakthrough. - Probenecid: may increase meropenem plasma concentrations, heightening toxicity risk.

Moderate Interactions (Monitor Closely): - Aminoglycosides: combined nephrotoxic potential requires renal function monitoring. - Loop diuretics: may enhance ototoxicity when used together. - Anticoagulants (warfarin): monitor INR as meropenem can affect coagulation parameters. - Oral contraceptives: may reduce efficacy; advise additional contraceptive measures.